The test uses fluid taken from patients to identify this complex, which may be associated with inflammation due to cartilage and spinal disc damage or degeneration. The patent includes diagnostic kit claims for detecting the Fibronectin and Aggrecan Complex and can be used to pinpoint the source of musculoskeletal pain.
More Articles on Pain Management:
8 Benchmarks for Low Back Pain Injections
Maintaining Quality at Pain Centers: Q&A With Dr. Edward Tavel of Pain Specialists of Charleston
Kentucky Society for Interventional Pain Physicians Tackles Opioid Prescribing
Patent Approved for Cytonics’ Diagnostic Spine & Joint Pain Test
Biotechnology company Cytonics has received a patent related to its Fibronectin-Aggercan Complex Test, which detects the presence of Fibronectin-Aggrecan Complex in patients with spine or joint related pain.
